Oct 1, 2007 Issue
Does Pioglitazone Benefit Patients With Type 2 Diabetes? [Cochrane for Clinicians]

Pioglitazone produces a reduction in A1C levels similar to that produced by other drugs. One trial found that although pioglitazone, used as an adjunct to other antihyperglycemic medications, may lead to a statistically significant reduction in morbidity and mortality in patients with established ma...

Sep 15, 2007 Issue
Sitagliptin (Januvia) for the Treatment of Patients with Type 2 Diabetes [STEPS]

Sitagliptin may be useful as second-line or third-line therapy in patients with a mildly elevated A1C level (less than 9 percent) who do not reach their A1C goal with first-line therapy (metformin). Sitagliptin will decrease postprandial blood glucose and mildly lower fasting blood glucose for a total A1C reduction around 0.8 percent.

Sep 1, 2007 Issue
Management of Type 2 Diabetes in Youth: An Update [Article]

Although type 1 diabetes historically has been more common in patients eight to 19 years of age, type 2 diabetes is emerging as an important disease in this group. Type 2 diabetes accounts for 8 to 45 percent of new childhood diabetes. This article is an update from the National Diabetes Education P...

Aug 1, 2007 Issue
Alpha-glucosidase Inhibitors May Reduce the Risk of Type 2 Diabetes [Cochrane for Clinicians]

The literature shows that acarbose can reduce the risk of type 2 diabetes in patients with impaired glucose tolerance or impaired fasting glucose. However, it is unclear whether the drug stops or delays the development of the disease or masks the diagnosis. There is no evidence that acarbose use red...

Jul 15, 2007 Issue
Home Monitoring of Glucose and Blood Pressure [Article]

Home monitoring of blood glucose and blood pressure levels can provide patients and physicians with valuable information in the management of diabetes mellitus and hypertension. Home monitoring allows patients to play an active role in their care and may improve treatment adherence and clinical outc...

Jun 15, 2007 Issue
Therapies for Diabetes: Pramlintide and Exenatide [Article]

The American Diabetes Association currently recommends an A1C goal of less than 7 percent. However, many patients are unable to achieve this goal by using oral drug combinations or diet and exercise, leaving insulin as the only treatment option. In most cases, insulin is initiated later in therapy b...

May 15, 2007 Issue
Insulin Inhalation Powder (Exubera) for Diabetes Mellitus [STEPS]

Inhaled insulin provides an alternative route of administration for rapid-acting insulin but offers no other benefit over available insulin therapy. It may reduce, but not eliminate, the need for self-injection in patients with type 1 diabetes. In patients with type 2 diabetes, the risk of hypoglyce...

Feb 1, 2007 Issue
The Role of Exercise in Patients with Type 2 Diabetes [Cochrane for Clinicians]

Regular exercise reduces A1C levels, adiposity, and triglyceride levels. However, no research has definitively proved a benefit of exercise on patient-oriented outcomes such as diabetes-related morbidity and mortality.

Jan 15, 2007 Issue
CDC Releases Data on Visual Impairment in Patients with Diabetes [Practice Guidelines]

The Centers for Disease Control and Prevention (CDC) has released data on visual impairment in patients with diabetes. Patients with diabetes are more likely to be visually impaired than those who do not have the disease.

Dec 15, 2006 Issue
Pregabalin (Lyrica) for the Management of Pain Associated with Diabetic Neuropathy [STEPS]

Pregabalin is safe and effective for the management of neuropathic pain associated with diabetic peripheral neuropathy. Drawbacks include the cost and the lack of studies demonstrating equivalence or superiority to other treatments. However, pregabalin’s ease of dosing titration, minimal drug intera...

Pages: Previous 1 ... 9 10 11 12 13 14 15 16 17 18 19 Next

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now